• Oaktree Acquisition III Life Sciences posted net income of USD 1.39 million for quarter ended March 31, 2026, down from USD 1.66 million a year earlier.
• Interest earned on cash held in trust account fell to USD 1.85 million from USD 2.1 million in prior-year quarter.
• General and administrative expenses rose to USD 456,538 from USD 444,802.
• Trust account balance stood at USD 203.41 million as of March 31, 2026, with USD 1.28 million of cash held outside trust.
• Going-concern warning flagged deadline to consummate a business combination by Oct. 25, 2026, with potential liquidation if no deal is completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oaktree Acquisition III Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-221814), on May 13, 2026, and is solely responsible for the information contained therein.